Skip to main content

Articles

Page 14 of 108

  1. Earlier age at onset of pubertal events and longer intervals between them (tempo) have been associated with increased breast cancer risk. It is unknown whether the timing and tempo of puberty are associated wi...

    Authors: Lauren C. Houghton, Seungyoun Jung, Rebecca Troisi, Erin S. LeBlanc, Linda G. Snetselaar, Nola M. Hylton, Catherine Klifa, Linda Van Horn, Kenneth Paris, John A. Shepherd, Robert N. Hoover and Joanne F. Dorgan
    Citation: Breast Cancer Research 2019 21:122
    Content type: Research article Published on:

  2. In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC.

    Authors: William Jacot, Paul Cottu, Frederique Berger, Coraline Dubot, Laurence Venat-Bouvet, Alain Lortholary, Hugues Bourgeois, Marc Bollet, Veronique Servent, Elisabeth Luporsi, Marc Espié, Severine Guiu, Veronique D’Hondt, Veronique Dieras, Marie-Paule Sablin, Etienne Brain…
    Citation: Breast Cancer Research 2019 21:121
    Content type: Research article Published on:

  3. Lobular carcinoma in situ (LCIS) of the breast is a risk factor of developing invasive breast cancer. We evaluated the racial differences in the risks of subsequent invasive breast cancer following LCIS.

    Authors: Vanessa Dania, Ying Liu, Foluso Ademuyiwa, Jason D. Weber and Graham A. Colditz
    Citation: Breast Cancer Research 2019 21:120
    Content type: Research article Published on:

    The Letter to this article has been published in Breast Cancer Research 2020 22:24

  4. Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. ...

    Authors: Jin Sun Lee, Susan E. Yost, Suzette Blanchard, Daniel Schmolze, Hongwei Holly Yin, Raju Pillai, Kim Robinson, Aileen Tang, Norma Martinez, Jana Portnow, Wei Wen, John H. Yim, Heather Ann Brauer, Yuqi Ren, Thehang Luu, Joanne Mortimer…
    Citation: Breast Cancer Research 2019 21:119
    Content type: Research article Published on:

  5. Physical activity (PA) before and after breast cancer diagnosis has been reported to be associated with lower mortality. However, whether changes in the activity after diagnosis impact prognosis is unclear and...

    Authors: Audrey Y. Jung, Sabine Behrens, Martina Schmidt, Kathrin Thoene, Nadia Obi, Anika Hüsing, Axel Benner, Karen Steindorf and Jenny Chang-Claude
    Citation: Breast Cancer Research 2019 21:117
    Content type: Research article Published on:

  6. Given that breast cancer and normal dense fibroglandular tissue have similar radiographic attenuation, we examine whether automated volumetric density measures identify a differential change between breasts in...

    Authors: Kathleen R. Brandt, Christopher G. Scott, Diana L. Miglioretti, Matthew R. Jensen, Amir P. Mahmoudzadeh, Carrie Hruska, Lin Ma, Fang Fang Wu, Steven R. Cummings, Aaron D. Norman, Natalie J. Engmann, John A. Shepherd, Stacey J. Winham, Karla Kerlikowske and Celine M. Vachon
    Citation: Breast Cancer Research 2019 21:118
    Content type: Research article Published on:

  7. Triple-negative breast cancer has extremely high risk of relapse due to the lack of targeted therapies, intra- and inter-tumoral heterogeneity, and the inherent and acquired resistance to therapies. In this st...

    Authors: Agnieszka Morgenroth, Ebru Tinkir, Andreas T. J. Vogg, Ramya Ambur Sankaranarayanan, Fatima Baazaoui and Felix M. Mottaghy
    Citation: Breast Cancer Research 2019 21:116
    Content type: Research article Published on:

  8. Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patien...

    Authors: Jung Ok Lee, Min Ju Kang, Won Seok Byun, Shin Ae Kim, Il Hyeok Seo, Jeong Ah. Han, Ji Wook Moon, Ji Hae Kim, Su Jin Kim, Eun Jung Lee, Serk In Park, Sun Hwa Park and Hyeon Soo Kim
    Citation: Breast Cancer Research 2019 21:115
    Content type: Research article Published on:

  9. Oncotype DX (ODx) is a 12-gene assay assessing the recurrence risk (high, intermediate, and low) of ductal carcinoma in situ (pre-invasive breast cancer), which guides clinicians regarding prescription of radi...

    Authors: Haojia Li, Jon Whitney, Kaustav Bera, Hannah Gilmore, Mangesh A. Thorat, Sunil Badve and Anant Madabhushi
    Citation: Breast Cancer Research 2019 21:114
    Content type: Research article Published on:

  10. Distant metastatic disease is frequently observed in inflammatory breast cancer (IBC), with a poor prognosis as a consequence. The aim of this study was to analyze the association of hormone receptor (HR) and ...

    Authors: D. J. P. van Uden, M. C. van Maaren, L. J. A. Strobbe, P. Bult, J. J. van der Hoeven, S. Siesling, J. H. W. de Wilt and C. F. J. M. Blanken-Peeters
    Citation: Breast Cancer Research 2019 21:113
    Content type: Research article Published on:

  11. Heterogeneity is a common finding within tumours. We evaluated the imaging features of tumours based on the decomposition of tumoural dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data to iden...

    Authors: Ming Fan, Pingping Xia, Bin Liu, Lin Zhang, Yue Wang, Xin Gao and Lihua Li
    Citation: Breast Cancer Research 2019 21:112
    Content type: Research article Published on:

  12. Screening mammography works better in fatty than in dense breast tissue. Computerized assessment of parenchymal texture is a non-subjective method to obtain a refined description of breast tissue, potentially ...

    Authors: My von Euler-Chelpin, Martin Lillholm, Ilse Vejborg, Mads Nielsen and Elsebeth Lynge
    Citation: Breast Cancer Research 2019 21:111
    Content type: Research article Published on:

  13. The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18–30, pa...

    Authors: Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park and Yikyung Park
    Citation: Breast Cancer Research 2019 21:110
    Content type: Research article Published on:

  14. Bone morphogenetic proteins (BMPs) have been reported to maintain epithelial integrity and to antagonize the transforming growth factor β (TGFβ)-induced epithelial to mesenchymal transition. The expression of ...

    Authors: Jiang Ren, Marcel Smid, Josephine Iaria, Daniela C. F. Salvatori, Hans van Dam, Hong Jian Zhu, John W. M. Martens and Peter ten Dijke
    Citation: Breast Cancer Research 2019 21:109
    Content type: Research article Published on:

  15. The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed.

    Authors: Barbara Adamo, Meritxell Bellet, Laia Paré, Tomás Pascual, Maria Vidal, José A. Pérez Fidalgo, Salvador Blanch, Noelia Martinez, Laura Murillo, Patricia Gómez-Pardo, Ana López-González, Kepa Amillano, Jordi Canes, Patricia Galván, Blanca González-Farré, Xavier González…
    Citation: Breast Cancer Research 2019 21:108
    Content type: Research article Published on:

  16. The introduction of next-generation sequencing has resulted in testing multiple genes simultaneously to identify inherited pathogenic variants (PVs) in cancer susceptibility genes. PVs with low minor allele fr...

    Authors: Felipe Batalini, Ellie G. Peacock, Lindsey Stobie, Alison Robertson, Judy Garber, Jeffrey N. Weitzel and Nadine M. Tung
    Citation: Breast Cancer Research 2019 21:107
    Content type: Review Published on:

  17. To evaluate the diagnostic performance of radiomic signatures extracted from contrast-enhanced magnetic resonance imaging (CE-MRI) for the assessment of breast cancer receptor status and molecular subtypes.

    Authors: Doris Leithner, Joao V. Horvat, Maria Adele Marino, Blanca Bernard-Davila, Maxine S. Jochelson, R. Elena Ochoa-Albiztegui, Danny F. Martinez, Elizabeth A. Morris, Sunitha Thakur and Katja Pinker
    Citation: Breast Cancer Research 2019 21:106
    Content type: Research article Published on:

  18. In the USA, the breast cancer mortality rate is 41% higher for African-American women than non-Hispanic White women. While numerous gene expression studies have classified biological features that vary by race...

    Authors: Maya A. Barrow, Megan E. Martin, Alisha Coffey, Portia L. Andrews, Gieira S. Jones, Denise K. Reaves, Joel S. Parker, Melissa A. Troester and Jodie M. Fleming
    Citation: Breast Cancer Research 2019 21:105
    Content type: Research article Published on:

  19. Breast cancer remains as one of the most lethal types of cancer in women. Among various subtypes, triple-negative breast cancer (TNBC) is the most aggressive and hard to treat type of breast cancer. Mechanisti...

    Authors: Chinnadurai Mani, Shirisha Jonnalagadda, Jojireddy Lingareddy, Sanjay Awasthi, William H. Gmeiner and Komaraiah Palle
    Citation: Breast Cancer Research 2019 21:104
    Content type: Research article Published on:

  20. Solid tumors produce proteins that can induce the accumulation of bone marrow-derived cells in various tissues, and these cells can enhance metastatic tumor growth by several mechanisms. 4T1 murine mammary tum...

    Authors: Momir Bosiljcic, Rachel A. Cederberg, Melisa J. Hamilton, Nancy E. LePard, Bryant T. Harbourne, Jenna L. Collier, Elizabeth C. Halvorsen, Rocky Shi, S. Elizabeth Franks, Ada Y. Kim, Judit P. Banáth, Mark Hamer, Fabio M. Rossi and Kevin L. Bennewith
    Citation: Breast Cancer Research 2019 21:103
    Content type: Research article Published on:

  21. Diffusion-weighted imaging (DWI) can increase breast MRI diagnostic specificity due to the tendency of malignancies to restrict diffusion. Diffusion tensor imaging (DTI) provides further information over conve...

    Authors: Jing Luo, Daniel S. Hippe, Habib Rahbar, Sana Parsian, Mara H. Rendi and Savannah C. Partridge
    Citation: Breast Cancer Research 2019 21:102
    Content type: Research article Published on:

  22. The incidence of brain metastases in breast cancer (BCBM) patients is increasing. These patients have a very poor prognosis, and therefore, identification of blood-based biomarkers, such as circulating tumor c...

    Authors: Carlotta Riebensahm, Simon A. Joosse, Malte Mohme, Annkathrin Hanssen, Jakob Matschke, Yvonne Goy, Isabell Witzel, Katrin Lamszus, Jolanthe Kropidlowski, Cordula Petersen, Anja Kolb-Kokocinski, Sascha Sauer, Kerstin Borgmann, Markus Glatzel, Volkmar Müller, Manfred Westphal…
    Citation: Breast Cancer Research 2019 21:101
    Content type: Research article Published on:

  23. Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade wi...

    Authors: Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Poly A. Niravath, Jorge G. Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani…
    Citation: Breast Cancer Research 2019 21:100
    Content type: Research article Published on:

  24. Stromal interaction molecule (STIM) 2 is a key calcium-sensing molecule that regulates the stabilization of calcium ions (Ca2+) and therefore regulates downstream Ca2+-associated signaling and cellular events. We...

    Authors: Yutian Miao, Qiang Shen, Siheng Zhang, Hehai Huang, Xiaojing Meng, Xianchong Zheng, Zhuocheng Yao, Zhanxin He, Sitong Lu, Chunqing Cai and Fei Zou
    Citation: Breast Cancer Research 2019 21:99
    Content type: Research article Published on:

  25. Circulating tumor cells (CTCs) represent a temporal “snapshot” of a patient’s cancer and changes that occur during disease evolution. There is an extensive literature studying CTCs in breast cancer patients, a...

    Authors: Vishnu C. Ramani, Clementine A. Lemaire, Melanie Triboulet, Kerriann M. Casey, Kyra Heirich, Corinne Renier, José G. Vilches-Moure, Rakhi Gupta, Aryana M. Razmara, Haiyu Zhang, George W. Sledge, Elodie Sollier and Stefanie S. Jeffrey
    Citation: Breast Cancer Research 2019 21:98
    Content type: Research article Published on:

  26. Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete respo...

    Authors: Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T. H. B. M. Smit, Elma Meershoek-Klein Kranenbarg, Joan B. Heijns, Laurence J. C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. A. E. Pepels, Hanneke W. M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit-Jan Liefers…
    Citation: Breast Cancer Research 2019 21:97
    Content type: Research article Published on:

  27. The long time from exposure to potentially harmful chemicals until breast cancer occurrence poses challenges for designing etiologic studies and for implementing successful prevention programs. Growing evidenc...

    Authors: Mary Beth Terry, Karin B. Michels, Julia Green Brody, Celia Byrne, Shiuan Chen, D. Joseph Jerry, Kristen M. C. Malecki, Mary Beth Martin, Rachel L. Miller, Susan L. Neuhausen, Kami Silk and Amy Trentham-Dietz
    Citation: Breast Cancer Research 2019 21:96
    Content type: Review Published on:

  28. Breast cancer is a common disease with a relatively good prognosis. Therefore, understanding the spectrum of diseases and mortality among breast cancer patients is important, though currently incomplete. We sy...

    Authors: Haomin Yang, Yudi Pawitan, Wei He, Louise Eriksson, Natalie Holowko, Per Hall and Kamila Czene
    Citation: Breast Cancer Research 2019 21:95
    Content type: Research article Published on:

  29. Human epidermal growth factor receptor-2 (HER2)-targeted therapies prolong survival in HER2-positive breast cancer patients. Benefit stems primarily from improved control of systemic disease, but up to 50% of ...

    Authors: Aadya Nagpal, Richard P. Redvers, Xiawei Ling, Scott Ayton, Miriam Fuentes, Elnaz Tavancheh, Irmina Diala, Alshad Lalani, Sherene Loi, Steven David, Robin L. Anderson, Yvonne Smith, Delphine Merino, Delphine Denoyer and Normand Pouliot
    Citation: Breast Cancer Research 2019 21:94
    Content type: Research article Published on:

  30. Improving breast cancer survival in sub-Saharan Africa (SSA) is urgently needed, requiring early diagnosis and improved access to treatment. However, data on the types of and barriers to receiving breast cance...

    Authors: Milena Foerster, Benjamin O. Anderson, Fiona McKenzie, Moses Galukande, Angelica Anele, Charles Adisa, Annelle Zietsman, Joachim Schuz, Isabel dos Santos Silva and Valerie McCormack
    Citation: Breast Cancer Research 2019 21:93
    Content type: Research article Published on:

  31. This study aimed to develop a prognostic model to predict the breast cancer-specific survival and overall survival for breast cancer patients in Asia and to demonstrate a significant difference in clinical out...

    Authors: Ching-Chieh Huang, Soa-Yu Chan, Wen-Chung Lee, Chun-Ju Chiang, Tzu-Pin Lu and Skye Hung-Chun Cheng
    Citation: Breast Cancer Research 2019 21:92
    Content type: Research article Published on:

  32. Women with dense breasts face a double risk for breast cancer; they are at a higher risk for development of breast cancer than those with less dense breasts, and there is a greater chance that mammography will...

    Authors: Olivier Alonzo-Proulx, James G. Mainprize, Jennifer A. Harvey and Martin J. Yaffe
    Citation: Breast Cancer Research 2019 21:91
    Content type: Research article Published on:

  33. The presence of tumor-infiltrating lymphocytes (TILs) is correlated with good prognosis and outcome after (immuno)therapy in triple-negative and HER2-positive breast cancer. However, the role of TILs in lumina...

    Authors: Marcelo Sobral-Leite, Izhar Salomon, Mark Opdam, Dinja T. Kruger, Karin J. Beelen, Vincent van der Noort, Ronald L. P. van Vlierberghe, Erik J. Blok, Daniele Giardiello, Joyce Sanders, Koen Van de Vijver, Hugo M. Horlings, Peter J. K. Kuppen, Sabine C. Linn, Marjanka K. Schmidt and Marleen Kok
    Citation: Breast Cancer Research 2019 21:90
    Content type: Research article Published on:

  34. Understanding the molecular alterations associated with breast cancer (BC) progression may lead to more effective strategies for both prevention and management. The current model of BC progression suggests a l...

    Authors: Xiaohui Tan, Zhongwu Li, Shuchang Ren, Katayoon Rezaei, Qing Pan, Andrew T. Goldstein, Charles J. Macri, Dengfeng Cao, Rachel F. Brem and Sidney W. Fu
    Citation: Breast Cancer Research 2019 21:89
    Content type: Research article Published on:

  35. Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer. Resistance to the drug leads to severe consequences, including disease re...

    Authors: Ami Hori, Masafumi Shimoda, Yasuto Naoi, Naofumi Kagara, Tomonori Tanei, Tomohiro Miyake, Kenzo Shimazu, Seung Jin Kim and Shinzaburo Noguchi
    Citation: Breast Cancer Research 2019 21:88
    Content type: Research article Published on:

  36. Approximately two thirds of patients with localized triple-negative breast cancer (TNBC) harbor residual disease (RD) after neoadjuvant chemotherapy (NAC) and have a high risk-of-recurrence. Targeted therapeut...

    Authors: Bradley A. Hancock, Yu-Hsiang Chen, Jeffrey P. Solzak, Mufti N. Ahmad, David C. Wedge, Dumitru Brinza, Charles Scafe, James Veitch, Rajesh Gottimukkala, Walt Short, Rutuja V. Atale, Mircea Ivan, Sunil S. Badve, Bryan P. Schneider, Xiongbin Lu, Kathy D. Miller…
    Citation: Breast Cancer Research 2019 21:87
    Content type: Research article Published on:

  37. Circulating tumor cells (CTCs) are important for metastatic dissemination of cancer. They can provide useful information, regarding biological features and tumor heterogeneity; however, their detection and cha...

    Authors: Galatea Kallergi, Vasileia Tsintari, Stelios Sfakianakis, Ekaterini Bei, Eleni Lagoudaki, Anastasios Koutsopoulos, Nefeli Zacharopoulou, Saad Alkahtani, Saud Alarifi, Christos Stournaras, Michalis Zervakis and Vassilis Georgoulias
    Citation: Breast Cancer Research 2019 21:86
    Content type: Research article Published on:

  38. Claudin-low breast cancer is a molecular subtype associated with poor prognosis and without targeted treatment options. The claudin-low subtype is defined by certain biological characteristics, some of which m...

    Authors: Christian Fougner, Helga Bergholtz, Raoul Kuiper, Jens Henrik Norum and Therese Sørlie
    Citation: Breast Cancer Research 2019 21:85
    Content type: Research article Published on:

  39. Vitamin D has been suggested to prevent and improve the prognosis of several cancers, including breast cancer. We have previously shown a U-shaped association between pre-diagnostic serum levels of vitamin D a...

    Authors: Linnea Huss, Salma Tunå Butt, Signe Borgquist, Karin Elebro, Malte Sandsveden, Ann Rosendahl and Jonas Manjer
    Citation: Breast Cancer Research 2019 21:84
    Content type: Research article Published on:

  40. Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from loc...

    Authors: Sergey Klimov, Islam M. Miligy, Arkadiusz Gertych, Yi Jiang, Michael S. Toss, Padmashree Rida, Ian O. Ellis, Andrew Green, Uma Krishnamurti, Emad A. Rakha and Ritu Aneja
    Citation: Breast Cancer Research 2019 21:83
    Content type: Research article Published on:

  41. Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor...

    Authors: Eva Tonsing-Carter, Kyle M. Hernandez, Caroline R. Kim, Ryan V. Harkless, Alyce Oh, Kathleen R. Bowie, Diana C. West-Szymanski, Mayra A. Betancourt-Ponce, Bradley D. Green, Ricardo R. Lastra, Gini F. Fleming, Sarat Chandarlapaty and Suzanne D. Conzen
    Citation: Breast Cancer Research 2019 21:82
    Content type: Research article Published on:

  42. Mammographic density (MD) is a strong breast cancer risk factor that reflects fibroglandular and adipose tissue composition, but its biologic underpinnings are poorly understood. Insulin-like growth factor bin...

    Authors: Manila Hada, Hannah Oh, Ruth M. Pfeiffer, Roni T. Falk, Shaoqi Fan, Maeve Mullooly, Michael Pollak, Berta Geller, Pamela M. Vacek, Donald Weaver, John Shepherd, Jeff Wang, Bo Fan, Amir Pasha Mahmoudzadeh, Serghei Malkov, Sally Herschorn…
    Citation: Breast Cancer Research 2019 21:81
    Content type: Research article Published on:

  43. A large collaborative analysis of data from 47 epidemiological studies concluded that longer duration of breastfeeding reduces the risk of developing breast cancer. Despite the strong epidemiological evidence,...

    Authors: Mustafa M. Basree, Neelam Shinde, Christopher Koivisto, Maria Cuitino, Raleigh Kladney, Jianying Zhang, Julie Stephens, Marilly Palettas, Allen Zhang, Hee Kyung Kim, Santiago Acero-Bedoya, Anthony Trimboli, Daniel G. Stover, Thomas Ludwig, Ramesh Ganju, Daniel Weng…
    Citation: Breast Cancer Research 2019 21:80
    Content type: Research article Published on:

  44. Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precisio...

    Authors: Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller and Teresa Puig
    Citation: Breast Cancer Research 2019 21:79
    Content type: Research article Published on:

  45. The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer...

    Authors: Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco…
    Citation: Breast Cancer Research 2019 21:78
    Content type: Research article Published on:

  46. The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signall...

    Authors: Ronan P. McLaughlin, Jichao He, Vera E. van der Noord, Jevin Redel, John A. Foekens, John W. M. Martens, Marcel Smid, Yinghui Zhang and Bob van de Water
    Citation: Breast Cancer Research 2019 21:77
    Content type: Research article Published on:

  47. Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at 4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen recep...

    Authors: Kelly J. Gregory, Amy L. Roberts, Erin M. Conlon, Jacob A. Mayfield, Mary J. Hagen, Giovanna M. Crisi, Brooke A. Bentley, Jeffrey J. Kane, Grace Makari-Judson, Holly S. Mason, Jun Yu, Lihua Julie Zhu, Karl Simin, Jacob P. S. Johnson, Ashraf Khan, Ben R. Schneider…
    Citation: Breast Cancer Research 2019 21:76
    Content type: Research article Published on:

  48. Comprehensive breast cancer risk prediction models enable identifying and targeting women at high-risk, while reducing interventions in those at low-risk. Breast cancer risk prediction models used in clinical ...

    Authors: Chang Ming, Valeria Viassolo, Nicole Probst-Hensch, Pierre O. Chappuis, Ivo D. Dinov and Maria C. Katapodi
    Citation: Breast Cancer Research 2019 21:75
    Content type: Research article Published on:

    The Letter to this article has been published in Breast Cancer Research 2020 22:35

    The Letter to this article has been published in Breast Cancer Research 2020 22:17

  49. SHC1 proteins (also called SHCA) exist in three functionally distinct isoforms (p46SHC, p52SHC, and p66SHC) that serve as intracellular adaptors for several key signaling pathways in breast cancer. Despite the...

    Authors: Kevin D. Wright, Bradley S. Miller, Sarah El-Meanawy, Shirng-Wern Tsaih, Anjishnu Banerjee, Aron M. Geurts, Yuri Sheinin, Yunguang Sun, Balaraman Kalyanaraman, Hallgeir Rui, Michael J. Flister and Andrey Sorokin
    Citation: Breast Cancer Research 2019 21:74
    Content type: Research article Published on:

  50. Neoadjuvant chemotherapy is increasingly given preoperatively to shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes associated with treatment and...

    Authors: Richard J. Bownes, Arran K. Turnbull, Carlos Martinez-Perez, David A. Cameron, Andrew H. Sims and Olga Oikonomidou
    Citation: Breast Cancer Research 2019 21:73
    Content type: Research article Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions

Breast Cancer Research

ISSN: 1465-542X

Contact us